When new, effective medicines providing safe treatment for widespread debilitating diseases, it is vitally important to ensure that everyone who needs such medicines has access to them. It was with this aim therefore that TBEC held a regional meeting on civil society capacity building for DR-TB. Existing TB treatments are incredibly gruelling for the patient, but medical innovations (shorter or safer treatments, new medicines, or more exact methods of diagnosis) can genuinely relieve a patient’s suffering. But what use are such innovations if patients aren’t able to access them? What use are new medicines if there’s no way for hospitals to buy them or any way to prescribe that they are needed? Any measurement of the success of innovative treatments has to be countered by an assessment of their accessibility. When everyone has access to new treatments, we can start to talk about how successful they are. Guidelines on DR-TB Treatment The recent WHO recommendations on drug-resistant TB (DR-TB) are the first in a long time that provide a genuine possibility to start to improve the treatment of DR-TB by using innovative and more effective medicines with less debilitating side effects. It is therefore vital that we do not waste time; More…